Encapsulation of Pioglitazone into Polymer–Nanoparticles for Potential Treatment of Atherosclerotic Diseases
- 5 May 2023
- journal article
- research article
- Published by American Chemical Society (ACS) in ACS Applied Bio Materials
- Vol. 6 (6) , 2111-2121
Abstract
Atherosclerosis is one of the most urgent global health subjects, causes millions of deaths worldwide, and is associated with enormous healthcare costs. Macrophages are the root cause for inflammatory onset and progression of the disease but are not addressed by conventional therapy. Therefore, we used pioglitazone, which is a drug initially used for diabetes therapies, but at the same time has great potential regarding the mitigation of inflammation. As yet, this potential of pioglitazone cannot be exploited, as drug concentrations at the target site in vivo are not sufficient. To overcome this shortcoming, we established PEG-PLA/PLGA-based nanoparticles loaded with pioglitazone and tested them in vitro. Encapsulation of the drug was analyzed by HPLC and revealed an outstanding encapsulation efficiency of 59% into the nanoparticles, which were 85 nm in size and had a PDI of 0.17. Further, uptake of our loaded nanoparticles in THP-1 macrophages was comparable to the uptake of unloaded nanoparticles. On the mRNA level, pioglitazone-loaded nanoparticles were superior to the free drug by 32% in increasing the expression of the targeted receptor PPAR-γ. Thereby the inflammatory response in macrophages was ameliorated. In this study, we take the first step toward an anti-inflammatory, causal antiatherosclerotic therapy, using the potential of the already established drug pioglitazone, and enable it to enrich at the target site by using nanoparticles. An additional crucial feature of our nanoparticle platform is the versatile modifiability of ligands and ligand density, to achieve an optimal active targeting effect in the future.Keywords
This publication has 64 references indexed in Scilit:
- Prediction of Drug–Polymer Miscibility through the use of Solubility Parameter based Flory–Huggins Interaction Parameter and the Experimental Validation: PEG as Model PolymerJournal of Pharmaceutical Sciences, 2013
- Nanoparticle-Mediated Delivery of Pioglitazone Enhances Therapeutic Neovascularization in a Murine Model of Hindlimb IschemiaArteriosclerosis, Thrombosis, and Vascular Biology, 2012
- Perspectives and opportunities for nanomedicine in the management of atherosclerosisNature Reviews Drug Discovery, 2011
- Polymer‐based therapeutics: nanoassemblies and nanoparticles for management of atherosclerosisWIREs Nanomedicine and Nanobiotechnology, 2011
- ESC/EAS Guidelines for the management of dyslipidaemias: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS)European Heart Journal, 2011
- PGC1β Mediates PPARγ Activation of Osteoclastogenesis and Rosiglitazone-Induced Bone LossCell Metabolism, 2010
- Actos Now for the prevention of diabetes (ACT NOW) studyBMC Endocrine Disorders, 2009
- Albumin-bound formulation of paclitaxel (Abraxane® ABI-007) in the treatment of breast cancerInternational Journal of Nanomedicine, 2009
- Regulation of Peroxisome Proliferator–Activated Receptor γ Activity by Losartan MetabolitesHypertension, 2006
- Inflammation, Atherosclerosis, and Coronary Artery DiseaseNew England Journal of Medicine, 2005